ImmunoID NeXT™ The Universal Cancer Immunogenomics Platform Advancing Modern Precision Oncology The ImmunoID NeXT Platform is designed specifically to enable the development of more efficacious cancer immunotherapies. While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones [...]
Oncology Research Services Comprehensive tumor profiling and analytics for targeted therapy One-stop tumor profiling A deeper understanding of cancer biology starts with comprehensive tumor characterization. We help better inform your cancer research studies with comprehensive tumor profiling assays powered by our Accuracy and Content Enhanced (ACE) Technology. [...]
ACE ImmunoID Precision immunogenomics A universal biomarker platform for immuno-oncology Patient response to cancer immunotherapies is currently reported as falling anywhere between 8% and 20%. Understanding the mechanisms by which tumors can evade the immune response and elucidating the complex dynamics of the tumor and its microenvironment are key [...]
Biomarker Discovery Solutions ACE ImmunoID Platform for Tumor Immunogenomics When one biomarker doesn’t tell the whole story Understanding response to cancer immunotherapies involves examining the interaction between mechanisms of tumor escape, the tumor microenvironment, and neoantigens. Gaining these molecular insights often requires analyzing data sourced from multiple platforms [...]
Genomics Solutions for Neoantigen Vaccines Getting neoantigen vaccines right The first step of developing personalized cancer vaccines is the identification of patient-specific neoantigens. These peptides can arise from anywhere in the genome, and methods for predicting which of these peptides will result in an efficacious vaccine are in early [...]
Genomics laboratories mainly rely on manual review and updates of their laboratory information management systems (LIMS) and other independent systems to track samples, workflows, and pipeline versions.
